OPK [NASD]
OPKO Health, Inc.
Index- P/E- EPS (ttm)-0.45 Insider Own0.40% Shs Outstand750.40M Perf Week-11.32%
Market Cap1.07B Forward P/E- EPS next Y-0.22 Insider Trans101.20% Shs Float416.76M Perf Month-24.19%
Income-316.90M PEG- EPS next Q-0.12 Inst Own24.70% Short Float / Ratio8.95% / 16.09 Perf Quarter-36.49%
Sales1.22B P/S0.87 EPS this Y-197.40% Inst Trans-2.78% Short Interest37.30M Perf Half Y-53.00%
Book/sh2.17 P/B0.65 EPS next Y53.20% ROA-13.60% Target Price5.44 Perf Year-65.53%
Cash/sh0.24 P/C5.91 EPS next 5Y12.00% ROE-19.10% 52W Range1.36 - 5.25 Perf YTD-70.69%
Dividend- P/FCF- EPS past 5Y11.90% ROI0.20% 52W High-73.14% Beta1.66
Dividend %- Quick Ratio1.30 Sales past 5Y9.70% Gross Margin27.90% 52W Low3.68% ATR0.10
Employees5767 Current Ratio1.50 Sales Q/Q-53.40% Oper. Margin-19.20% RSI (14)32.02 Volatility5.67% 5.92%
OptionableYes Debt/Eq0.15 EPS Q/Q-360.20% Profit Margin-26.00% Rel Volume2.78 Prev Close1.40
ShortableYes LT Debt/Eq0.10 EarningsNov 08 AMC Payout- Avg Volume2.32M Price1.41
Recom1.80 SMA20-16.00% SMA50-20.54% SMA200-45.12% Volume6,271,262 Change0.71%
Jan-24-22Downgrade Barrington Research Outperform → Mkt Perform
Jun-21-21Initiated Ladenburg Thalmann Buy $7
Nov-25-19Initiated Piper Jaffray Overweight $2.50
Mar-02-18Downgrade JP Morgan Neutral → Underweight
Sep-14-17Downgrade JP Morgan Overweight → Neutral
Jun-21-16Reiterated Standpoint Research Buy $16 → $18
Jun-03-16Initiated Standpoint Research Buy $16
Mar-31-16Reiterated Barrington Research Outperform $17 → $16
Oct-16-15Initiated JP Morgan Overweight $14
Sep-11-15Downgrade Jefferies Buy → Hold
Show Previous Ratings
Nov-29-22 10:47AM
Nov-16-22 05:08AM
Nov-09-22 08:39AM
Nov-08-22 08:30PM
05:35PM
04:05PM Loading…
04:05PM
Nov-01-22 08:00AM
Oct-30-22 08:04AM
Oct-03-22 07:17AM
Sep-26-22 10:38AM
Sep-15-22 04:05PM
Sep-05-22 12:28PM
Aug-31-22 04:50PM
Aug-23-22 10:30AM
Aug-17-22 01:51PM
04:29PM Loading…
Aug-16-22 04:29PM
Aug-11-22 08:30PM
Aug-09-22 11:56AM
09:14AM
Aug-05-22 04:00AM
Aug-04-22 07:35PM
04:05PM
Jul-25-22 04:05PM
Jul-21-22 11:50AM
Jun-02-22 08:00AM
May-11-22 11:00AM
May-10-22 12:56PM
01:30AM
May-09-22 05:35PM
04:05PM
09:23AM Loading…
09:23AM
May-05-22 04:05PM
May-03-22 06:15PM
May-02-22 07:45AM
Apr-22-22 09:48AM
Apr-21-22 05:25PM
Mar-28-22 01:05PM
Mar-25-22 06:15PM
Mar-16-22 07:30AM
Mar-05-22 07:48AM
Mar-03-22 06:15PM
Mar-01-22 06:00AM
Feb-28-22 12:00PM
Feb-25-22 09:28PM
Feb-24-22 09:30PM
06:10PM
04:05PM
Feb-18-22 06:15PM
03:16PM
Feb-17-22 08:00AM
Feb-16-22 11:20AM
11:07AM
Feb-15-22 11:53AM
11:08AM
Feb-10-22 03:01PM
Feb-08-22 08:15AM
Feb-03-22 08:30AM
06:55AM
Feb-02-22 06:15PM
Feb-01-22 12:25PM
11:43AM
Jan-27-22 06:15PM
05:33PM
10:27AM
Jan-24-22 04:44PM
02:06PM
12:48PM
05:49AM
Jan-21-22 04:30PM
09:16AM
Jan-20-22 08:00AM
Jan-18-22 09:38AM
09:38AM
07:00AM
Jan-05-22 04:05PM
01:38PM
Dec-27-21 11:07AM
Dec-23-21 01:56PM
08:00AM
Dec-09-21 12:00PM
Dec-08-21 08:00AM
Dec-06-21 08:00AM
Dec-03-21 07:16AM
Nov-30-21 10:13AM
Nov-29-21 10:25AM
08:00AM
Nov-01-21 09:12AM
Oct-29-21 02:05PM
06:31AM
Oct-28-21 06:15PM
04:15PM
Oct-25-21 10:57AM
Oct-12-21 08:00AM
Oct-05-21 06:50AM
Oct-04-21 01:01PM
Sep-27-21 09:45AM
09:23AM
Sep-24-21 04:24PM
Sep-21-21 02:30PM
Sep-15-21 10:50AM
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FROST PHILLIP MD ET ALCEO & ChairmanNov 22Buy1.49300,000446,673198,831,694Nov 23 07:10 AM
FROST PHILLIP MD ET ALCEO & ChairmanNov 09Buy1.60200,000319,424198,531,694Nov 10 06:56 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 27Buy1.82100,000182,006198,331,694Oct 28 06:49 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 19Buy1.72100,000172,069198,231,694Oct 20 06:24 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 14Buy1.72100,000171,917198,131,694Oct 17 07:14 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 13Buy1.79100,000179,367198,031,694Oct 14 06:57 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 12Buy1.73100,000172,722197,931,694Oct 13 07:43 AM
FROST PHILLIP MD ET ALCEO & ChairmanOct 07Buy1.7775,000132,624197,831,694Oct 11 07:47 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 26Buy1.8050,00089,979197,756,694Sep 27 07:29 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 23Buy1.8550,00092,313197,706,694Sep 26 06:59 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 22Buy1.9050,00094,837197,656,694Sep 23 07:20 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 21Buy1.9150,00095,492197,606,694Sep 22 07:39 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 20Buy1.9450,00096,888197,556,694Sep 21 07:23 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 19Buy1.9750,00098,554197,506,694Sep 20 07:20 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 15Buy2.06200,000412,900197,456,694Sep 16 07:42 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 02Buy2.14100,000214,138197,256,694Sep 06 07:50 AM
FROST PHILLIP MD ET ALCEO & ChairmanAug 17Buy2.54200,000507,949197,156,694Aug 18 08:22 AM
FROST PHILLIP MD ET ALCEO & ChairmanAug 05Buy2.29350,000802,103196,956,694Aug 08 08:05 AM
Nabel Gary J.Chief Innovation OfficerJun 22Buy2.49240,000597,39319,857,514Jun 24 07:52 PM
FROST PHILLIP MD ET ALCEO & ChairmanJun 21Buy2.39200,000478,857196,606,694Jun 22 06:59 AM
FROST PHILLIP MD ET ALCEO & ChairmanJun 16Buy2.31100,000231,327196,406,694Jun 17 08:11 AM
FROST PHILLIP MD ET ALCEO & ChairmanJun 13Buy2.36100,000236,498196,306,694Jun 14 08:05 AM
FROST PHILLIP MD ET ALCEO & ChairmanJun 06Buy2.79100,000279,227196,206,694Jun 07 07:29 AM
FROST PHILLIP MD ET ALCEO & ChairmanJun 01Buy2.9550,000147,614196,106,694Jun 02 08:08 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 31Buy3.0250,000151,177196,056,694Jun 01 07:28 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 25Buy2.9850,000148,866196,006,694May 26 08:16 AM
Nabel Gary J.Chief Innovation OfficerMay 18Buy2.9068,492198,62775,471May 19 04:28 PM
FROST PHILLIP MD ET ALCEO & ChairmanMay 18Buy2.8850,000143,984195,956,694May 19 07:32 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 16Buy2.98150,000446,794195,906,694May 17 06:33 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 13Buy3.00200,000599,316195,756,694May 16 07:17 AM
Nabel Gary J.Chief Innovation OfficerMay 12Buy2.656,97918,4946,979May 19 04:28 PM
FROST PHILLIP MD ET ALCEO & ChairmanMay 11Buy2.83400,0001,132,400195,556,694May 12 06:50 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 10Buy2.78400,0001,113,560195,156,694May 11 06:49 AM
Zerhouni Elias A.Vice Chairman and PresidentMay 10Buy2.7989,600250,39689,600May 11 09:01 PM
FROST PHILLIP MD ET ALCEO & ChairmanMar 14Buy3.0435,000106,317194,756,694Mar 15 07:33 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 11Buy3.13100,000312,865194,721,694Mar 14 07:16 AM
FROST PHILLIP MD ET ALCEO & ChairmanFeb 28Buy3.11100,000310,796194,621,694Mar 01 07:33 AM
FROST PHILLIP MD ET ALCEO & ChairmanFeb 25Buy3.09750,0002,315,325194,521,694Feb 28 07:59 AM
FROST PHILLIP MD ET ALCEO & ChairmanFeb 14Buy3.04100,000303,569193,771,694Feb 15 09:10 AM
FROST PHILLIP MD ET ALCEO & ChairmanFeb 01Buy3.03150,000455,009193,671,694Feb 02 07:18 AM
FROST PHILLIP MD ET ALCEO & ChairmanJan 26Buy2.98350,0001,041,817193,521,694Jan 27 08:12 AM